Blog

Co-led by SemperVirens Venture Capital and Next Ventures, with participation by Sanofi Ventures, Lux Capital, Civilization Ventures, How Women Invest and other notable investors

SAN FRANCISCO, CA / ACCESS Newswire / December 2, 2025 / Trial Library, an AI-enabled platform expanding access to clinical trials as a care option, announced a $10 million Series A funding round co-led by SemperVirens Venture Capital and Next Ventures, with participation from Sanofi Ventures, Lux Capital, Civilization Ventures, How Women Invest, Overwater Ventures and others. This investment, which brings total funding to date of $15 million, accelerates Trial Library’s mission to make clinical research a core part of standard of care – bridging access gaps for patients, empowering healthcare providers and aligning payers and biopharmaceutical sponsors around a more efficient and equitable research ecosystem.

“As a physician-scientist, I witnessed, first-hand, the significant impact clinical trials have on improved healthcare outcomes. At Trial Library, we’re building the connective tissue that links care delivery and clinical research,” said Dr. Hala Borno, CEO and founder of Trial Library. “This latest funding will enable us to advance our model where access to innovation is the standard, not the exception.”

Trial Library’s platform unlocks access to clinical trials in community-based clinical settings through AI-enabled provider activation, compliant eligible patient identification and longitudinal navigation throughout the trial lifecycle.Trial Library currently operates across 320+ clinics and 1,500+ providers nationwide and is rapidly expanding its network alongside growing partnerships with payers such as self-insured plans and health plans.

“Trial Library is the first technology company to unlock the payer market to effectively broaden the pool of patients who are considered for clinical trials,” said Allison Baum Gates, general partner of SemperVirens Venture Capital. “We’re excited to back a platform that aligns incentives and unites patients, providers, payers, and life-science partners around shared cost-savings and patient outcomes.”

Trial Library has partnered with leading global biopharmaceutical companies to accelerate R&D and enrollment. “Trial Library is a uniquely end-to-end platform, building the AI infrastructure that is accelerating access to the next generation of precision medicine,” said Cris De Luca, partner at Sanofi Ventures.

Since launching in 2022, Trial Library has demonstrated significant impact through strategic partnerships with leading healthcare organizations. The company’s work with The Oncology Institute generated 642 patient referrals in one year, while partnerships with American Oncology Network have identified tens of eligible patients for solid tumor trials in just the first quarter of implementation. Trial Library’s platform has also expanded its collaboration with Johnson & Johnson Innovative Medicine to support oncology clinical development and medical affairs programs, and in 2025 the company announced a collaboration with Texas Oncology to streamline clinical trial access through personalized patient navigation

“Trial Library’s approach aligns with the growing shift toward decentralized, community-based research,” said Lance Armstrong, managing partner at Next Ventures. They’re proving that AI and human navigation together can bring precision medicine to every corner of healthcare.”

Trial Library is committed to diversity and equity among patient populations, including a focus on underserved populations. This includes 69% of patient referrals being non-white, 29% on Medicaid and 44% requiring transportation support. This effort addresses critical gaps in clinical trial participation while reducing administrative burden on providers and transforming how community oncology practices engage with clinical research.

About Trial Library

Trial Library is an AI-platform that accelerates access to precision medicine. In collaboration with biopharmaceutical manufacturers, payers and health systems, Trial Library enables the delivery of clinical trials as a care option, advancing access to precision medicine, improving oncology outcomes and reducing the total cost of care. Backed by some of the leading venture capital firms in healthcare, Trial Library currently operates across 320+ clinics and 1,500+ providers nationwide. Learn more at www.triallibrary.com.

Media Contact

Lizi Sprague, Songue PR
lizi@songuepr.com

SOURCE: Trial Library

View the original press release on ACCESS Newswire

ESTERO, FLORIDA / ACCESS Newswire / December 2, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) (“Aspire” or the “Company”), a developer of a multi-faceted patent-pending drug delivery technology, is pleased to announce that on November 3, 2025, it submitted its Pre-IND meeting request and briefing package to the U.S. Food and Drug Administration (FDA). The submission concerns the Company’s lead product candidate, a fast-acting, high-dose sublingual aspirin formulation for the treatment of suspected acute myocardial infarction (AMI) and represents a significant milestone on the path to potential FDA approval.

The Pre-IND meeting initiates formal dialogue with the FDA and is intended to gain agency guidance on the clinical development strategy and confirm the proposed 505(b)(2) regulatory pathway for Aspire’s sublingual aspirin. Gaining this clarity is a critical step toward the Company’s goal of submitting a New Drug Application (NDA).

“Our clinical data is not just promising; it’s a breakthrough in MCI treatment. We demonstrated that our sublingual formulation begins to inhibit platelet aggregation in under two minutes, acting approximately four to five times as fast as chewed aspirin,” said Kraig Higginson, Interim CEO of Aspire Biopharma. “This rapid action, confirmed with a statistical significance of p<0.02, represents a clear and potentially life-saving advantage over the current standard of care. In a heart attack, every second saved translates to preserved heart muscle. We are eager to present this compelling evidence to the FDA and define an efficient path to bring this superior treatment to patients.”

Aspire’s confidence is rooted in the breakthrough final results of its recent clinical trial. The study showed that Aspire’s investigational product produced significantly higher and more rapid mean plasma concentrations of acetylsalicylic acid (ASA), the active form of aspirin, compared to chewed aspirin tablets (p<0.05). This was demonstrated clearly in the recent trial by the lowered levels of serum thromboxane B2 (TxB2), a key biomarker for reduced platelet accumulation, within the first two minutes after dosing (p<0.02) with Aspire’s sublingual aspirin, acting approximately four to five times faster than chewed conventional aspirin. This rapid pharmacological action demonstrates a clear and clinically meaningful superiority over the current standard of care.

The product was also observed to be safe and well-tolerated. These results underscore the potential for Aspire’s sublingual aspirin to provide a more rapid and reliable treatment for the 800,000+ people in the U.S. who suffer a heart attack each year.

The Company intends to pursue a 505(b)(2) regulatory pathway for its sublingual aspirin product. This streamlined pathway allows the FDA to consider data from previous studies on an already-approved drug, such as aspirin, which can potentially reduce the time and cost of development.

This milestone for the lead aspirin program also serves as a key validation of Aspire’s versatile sublingual delivery platform, which is being applied to a pipeline of other high-value programs.

About Aspire Biopharma Holdings, Inc.

Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma’s delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements.

For more information, please visit www.aspirebiolabs.com

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Aspire’s forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; and other risks and uncertainties set forth in “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

Aspire Biopharma Holdings, Inc.

Contact

Brett Maas
Hayden IR: (646) 536-7331
brett@haydenir.com

James Carbonara
Hayden IR: (646)-755-7412
james@haydenir.com

SOURCE: Aspire Biopharma Holdings, Inc.

View the original press release on ACCESS Newswire

New partnership marks a significant step forward in the shared mission to combat AI-enabled fraud and strengthen digital safety worldwide.

THE HAGUE, NL / ACCESS Newswire / December 2, 2025 / As scammers adopt increasingly sophisticated methods powered by artificial intelligence, global coordination and responsible innovation have become essential to protecting consumers. Today, the Global Anti-Scam Alliance (GASA) and OpenAI announce that OpenAI has joined GASA as a Foundation Member, marking a significant step forward in the shared mission to combat AI-enabled fraud and strengthen digital safety worldwide.

OpenAI is an AI research and deployment company whose mission is to ensure AI benefits all of humanity. The company heavily invests in safety and misuse prevention, including efforts to detect and disrupt malicious attempts to use AI systems for scams, phishing, fraud, and other harms. OpenAI also publicly shares lessons from this work to strengthen collective defenses and reinforce its commitment to transparency and responsible deployment.

“The rise of AI enabled scams demands coordinated action across technology, policy, and law enforcement. OpenAI’s efforts to detect and disrupt malicious use of AI systems align closely with our mission. Their decision to join GASA as a Foundation Member sends a strong signal that protecting consumers in the age of AI requires shared intelligence, shared responsibility, and shared purpose,” said Jorij Abraham, Managing Director of GASA.

“Scams are one of the fastest-growing threats people face online, and our tools are increasingly good at spotting them. That’s why OpenAI is joining the Global Anti-Scam Alliance, where we can share insights, strengthen our collective defenses, and help people stay safe. This work fits squarely within our mission to build AI tools that benefit all of humanity,” said Will McCants, Head of Intelligence and Investigations at OpenAI.

By joining GASA as a Foundation Member, OpenAI will contribute to global research, the global advisory board, and cross-sector collaboration focused on reducing the impact of AI-enabled scams. This partnership strengthens the collective effort to build safer digital ecosystems and ensure that innovation is supported by safeguards, accountability, and shared intelligence.

Read the full release here.

SOURCE: Global Anti-Scam Alliance

Related Images

View the original press release on ACCESS Newswire

Delivering unmatched convenience, efficiency, and expertise-all in one centralized hub for access control, security, and loading dock solutions.

DENVER, CO / ACCESS Newswire / December 2, 2025 / In a move designed to simplify how professionals source and service perimeter access, security, and loading dock solutions, Controlled Products Systems Group (CPSG), Multi-Fab Products, and NOVA Technology^TM have co-located operations in Atlanta, Georgia. This new multi-brand hub gives customers access to a complete range of products, parts, and technical expertise-all from trusted leaders in their respective industries.

Location:
980 Cobb Pl Blvd NW
Ste 160
Kennesaw, GA 30144

The Atlanta hub creates a seamless, one-stop destination for customers, combining convenience, efficiency, and expert support under one roof. Customers can now source everything they need-from door parts and loading dock equipment to access control systems-while benefiting from faster delivery, improved availability, and personalized in-person support across the Southeast.

“Our customers’ time is valuable. By bringing together three powerhouse brands in one central location, we’re providing them with access to the resources and expertise they need to keep their work moving and businesses running strong,” said Andy Martin, President, Controlled Products Systems Group. “It’s not just about convenience. Whether they need loading dock or specialty door parts, dock equipment, or perimeter security products, they’ll find the right products, the right parts, and the right expertise in Atlanta.”

Together, these companies offer a complete lineup of industry-leading solutions. CPSG provides a broad range of access control systems, gate operators, crash and HVM barriers, parking control equipment, long-range RFID, and residential and commercial door automation from today’s leading manufacturers. Multi-Fab Products supplies aftermarket loading dock parts, accessories, and specialty door replacements, giving service teams reliable access to the components they need to keep facilities operating safely and efficiently. NOVA Technology delivers durable, high-performance loading dock equipment-including vehicle restraints, dock seals, shelters, and levelers-engineered for maximum safety, energy efficiency, and reliability.

“This shared facility brings together the trusted brands and expertise our customers rely on,” said Adam Schrot, Operations Vice President and General Manager, Multi-Fab Products. “We’re proud to make it easier than ever for them to access the best products and deliver exceptional service to their own clients.”

Atlanta’s co-location marks a major milestone in expanding local support, reducing downtime, and improving service capabilities across the Southeast. Customers now have one trusted destination for doors, docks, and perimeter access solutions-everything they need to keep their businesses moving forward.

For company-specific inquiries, contact:
Controlled Products Systems Group: 404.603.6477
Multi-Fab Products: 262.502.1707
Nova Technology: 262.502.1591

About Controlled Products Systems Group (CPSG)
Controlled Products Systems Group is the largest wholesale distributor of perimeter access control and security equipment in the United States, serving authorized dealers from coast to coast through 33 locations. CPSG offers the industry’s most trusted brands, expert technical support, and professional training to help customers grow their businesses.
Learn more:controlledproducts.com

About Multi-Fab Products (MFP)
Headquartered in Menomonee Falls, Wisconsin, Multi-Fab Products is a global manufacturer and supplier of a complete line of aftermarket parts and accessories for all major manufacturers of loading dock equipment and specialty door parts. MFP provides one-stop access to everything customers need to keep docks operating safely, efficiently, and reliably.
Learn more:multi-fab.com

About NOVA Technology^TM
For over 30 years, NOVA Technology has been a leading international manufacturer and distributor of loading dock equipment and accessories. Designed for safety, security, and performance, NOVA products are trusted across commercial facilities worldwide and supported by a nationwide network of trained dealers and installers.
Learn more:novalocks.com

Contact Information

Jamie Emerson
Sr. Marketing Communications Manager
jamie.emerson@controlledproducts.com
800.622.5335

SOURCE: Controlled Products Systems Group

View the original press release on ACCESS Newswire

New Mesa campus deepens Strive’s roots in Arizona, expands production capabilities, and accelerates job creation as the company surpasses 700,000 sq. ft. of national operations.

MESA, AZ / ACCESS Newswire / December 2, 2025 / Strive Pharmacy, a national leader in patient-centered pharmaceutical compounding, officially broke ground today on its new 350,000-square-foot headquarters and advanced compounding facility in Mesa, Arizona. The milestone marks a significant step in Strive’s long-term growth plan and deepens its commitment to the state where the company was founded.

More than just an expansion of physical space, the new Arizona headquarters represents Strive’s continued investment in innovation, workforce development, and world-class patient care. The facility will serve as the company’s operational home base, supporting national fulfillment, accelerating production capacity, and creating significant new job opportunities across the Greater Phoenix region.

“This new headquarters is an investment in Arizona, in our team, and in the future of patient-focused medicine,” said Nate Hill, CEO and co-founder of Strive Pharmacy. “Arizona is where Strive started, and this project allows us to build the infrastructure, technology, and talent necessary to meet growing demand while staying true to our mission never to settle, especially when people’s health is at stake.”

The building will give Strive a unique advantage-meeting the needs of existing and growing demand for personalized care, while also being built from the ground up to enable operational agility to pivot, adjust, and adapt with patient needs, industry advancements, or potential drug shortages.

Attendees of an upcoming groundbreaking event will receive a first look at Strive’s plans for the new campus, including dedicated spaces for state-of-the-art compounding, fulfillment automation, training facilities, and expanded administrative operations. Community leaders, partners, healthcare providers, and team members will gather for a brief ceremony, a discussion on Strive’s vision for the future, and a light brunch.

“When we invest in our facilities, we’re investing directly in patients and providers,” said Mike Walker, President and co-founder of Strive Pharmacy. “This headquarters will anchor the systems, quality controls, and service levels that define Strive. It’s a home built for the next decade of innovation.”

The Arizona groundbreaking comes on the heels of major expansion milestones for Strive. Within the next 12 months, the company will operate more than 700,000 square feet of advanced pharmaceutical facilities nationwide, including a newly acquired 275,000-square-foot cGMP manufacturing site in Alachua, FL, and a recently expanded Tampa location designed to enhance patient experience and fulfillment speed across the Southeast.

“Quality isn’t a step in our process, it is the process,” said Matthew Montes de Oca, Chief Compliance/Clinical Officer at Strive Pharmacy. “From rigorous weekly potency testing to independent sterility validation, every safeguard we build into this facility has one purpose: ensuring patients receive medicine that is precisely made, thoroughly verified, and genuinely personal to their needs.”

Together, these investments position Strive as the largest and most advanced compounding pharmacy network in the United States, supporting unprecedented production scale and elevated quality standards.

“At Strive, we’re not simply growing, we’re evolving,” added Walker. “Every square foot we build is designed to improve access, elevate quality, and deliver care with transparency and compassion.”

About Strive Pharmacy

Strive Pharmacy is on a mission to make personalized medicine mainstream. With a strong focus on quality, customization, and a commitment to putting people over profit, Strive Compounding Pharmacy is redefining what personalized healthcare can look like-one prescription at a time. Whether through brick-and-mortar partnerships or innovative telehealth collaborations, Strive Compounding Pharmacy continues to push the boundaries of what’s possible in modern medicine. For more information, visit Strive Compounding Pharmacy’s website at https://www.strivepharmacy.com/.

Media Contact:
Zach Shurtleff
Chief Marketing Officer
zach@strivepharmacy.com
www.strivepharmacy.com

SOURCE: Strive Pharmacy

View the original press release on ACCESS Newswire

NEW YORK, NY / ACCESS Newswire / December 2, 2025 / Recycled plastics should be one of the most profitable materials in the global supply chain. Every major brand wants more of it, governments are pushing mandates, and consumers expect companies to cut reliance on virgin polymers. Yet recycled plastics still sell at a discount. Markets don’t fully trust the labels, suppliers can’t prove what they’re shipping, and buyers assume they’re paying for content that might not be real. The spread between what recycled plastics should be worth and what companies actually earn has turned into a persistent profit gap. SMX (NASDAQ:SMX) is closing that gap by giving plastics something they’ve never had. They get a verifiable identity that survives every transformation.

The recycled plastics market is full of claims without certainty. Suppliers insist their pellets contain 30%-50% recycled content, but they lack molecular evidence to support that claim. Brands reveal sustainability commitments, but they rely on third-party forms that don’t reflect what happens across international recycling streams. Governments demand accuracy, but they’re stuck reviewing documentation that’s often outdated or fragmented. Companies lose money because they can’t prove value. Buyers discount prices because they can’t trust inputs. That cycle has held the entire sector back for years.

SMX changes that by embedding a molecular-level identifier into plastics that stays intact through every process. The identity doesn’t wash out during shredding. It doesn’t disappear during melting. It survives extrusion, molding, and reprocessing. When a batch of recycled pellets arrives at a manufacturer, identity confirmation verifies exactly what the plastic contains and where it originated. Suddenly, recycled content is no longer a claim. It’s proof. And proof commands a premium.

Why Trust Drives Value in Plastics Markets

The plastics sector, more than almost any other, depends on trust because recycled feedstocks are inconsistent across regions, processors, and collection systems. Two suppliers may list the same grade on a sheet, but the actual material can behave differently in production. That uncertainty costs brands time, money, and credibility. When buyers can’t verify recycled content, they reduce their bids. When manufacturers can’t guarantee consistency, they overengineer products to compensate. When regulators can’t validate reports, they add layers of reporting that slow down the entire system.

This is where strategic partnerships show the practical impact of material identity. SMX’s collaboration with Tradepro in the United States proves how authentication changes market behavior. Manufacturers that used to hedge against uncertainty can, if all goes as planned, choose verified recycled plastics that carry embedded truth. The material isn’t anonymous anymore. It arrives with evidence. That shift alone lifts margins for suppliers who previously watched their prices suppressed by doubt.

The REDWAVE collaboration in Austria shows another side of the advantage. High-speed optical sorting gains precision when the material entering the system carries its own identification. Instead of relying on shape or color, the line reads molecular identity. That allows more accurate separation, more consistent output, and higher-grade recycled plastics that fetch stronger pricing. Markets begin rewarding quality because quality becomes measurable.

When plastics tell the truth about themselves, the value follows the evidence. Buyers start paying more for verified content. Brands start meeting sustainability goals without fear of greenwashing allegations. Recyclers start commanding higher margins for authenticated outputs. Trust isn’t a belief anymore. It’s a property.

How Proof Rewrites Sustainability and Profitability

The plastics industry has spent a decade trying to balance sustainability with economic reality. Companies want to increase recycled content, but they can’t expose themselves to risk. Regulators want accuracy, but they can’t rely on reporting alone. Investors want transparency, but they need real data, not estimates. Every stakeholder wants the same thing. They want evidence without friction.

That’s why the A*STAR program in Singapore became a breakthrough moment. When SMX’s identity technology was deployed within national-scale circularity pilots, recycled plastics gained trackable lineage across collection, recovery, reuse, and manufacturing. The system didn’t assume accuracy. It verified it. A plastic bottle didn’t disappear into the system. It traveled through it with identity intact.

That level of truth gives governments a way to enforce recycling goals without slowing down industry. It gives brands a way to meet their commitments with confidence. It gives recyclers a way to get paid what their material is truly worth. The result is a plastics market that finally behaves like a real commodity market. Verified content sells at a premium because the risk disappears. Supply chains run cleaner because fraud becomes pointless. Regulators gain visibility without adding complexity. Investors see rising margins instead of structural discounts. Verification becomes the economic engine that the plastics market has been missing.

That closes the gap between what recycled plastics should be worth and what companies actually earn. SMX built the technology that transforms recycled plastics from a discounted material into a premium one. When the market knows the truth, the market pays for the truth. The companies able to prove it will redefine the economics of sustainability. And, more importantly, make money at the same time.

About SMX

As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

Forward-Looking Statements

The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: matters relating to the Company’s fight against abusive and possibly illegal trading tactics against the Company’s stock; successful launch and implementation of SMX’s joint projects with manufacturers and other supply chain participants of steel, rubber and other materials; changes in SMX’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; SMX’s ability to develop and launch new products and services, including its planned Plastic Cycle Token; SMX’s ability to successfully and efficiently integrate future expansion plans and opportunities; SMX’s ability to grow its business in a cost-effective manner; SMX’s product development timeline and estimated research and development costs; the implementation, market acceptance and success of SMX’s business model; developments and projections relating to SMX’s competitors and industry; and SMX’s approach and goals with respect to technology. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company’s shares on Nasdaq; changes in applicable laws or regulations; any lingering effects of the COVID-19 pandemic on SMX’s business; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which SMX operates; the risk that SMX and its current and future collaborators are unable to successfully develop and commercialize SMX’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that SMX is unable to secure or protect its intellectual property; the possibility that SMX may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in SMX’s filings from time to time with the Securities and Exchange Commission.

Contact: info@securitymattersltd.com

SOURCE: SMX (Security Matters) Public Limited

View the original press release on ACCESS Newswire

Jaguar’s requesting advice from EMA on EU approval pathway for general diarrhea of FDA conditionally approved Canalevia^®

A novel non-antibiotic approach to diarrhea treatment is important because there are no FDA-approved drugs to treat general diarrhea in dogs, the second most common reason for visits to veterinary emergency hospitals

SAN FRANCISCO, CA / ACCESS Newswire / December 2, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar), today announced that its Italian subsidiary, Napo Therapeutics S.p.A., has submitted a request to the European Medicines Agency (EMA) to have the EMA’s Committee for Veterinary Medicinal Products (CVMP) provide scientific advice regarding the company’s plan to pursue approval of Canalevia (crofelemer delayed-release tablets) in the European Union for treatment of general diarrhea in dogs based on data from a study Jaguar completed in 200 dogs in 2017. The request asks that the CVMP review the company’s plan and related data during the CVMP’s scheduled meeting in March 2026.

The EMA is the EU’s equivalent of the U.S. Food and Drug Administration (FDA). Canalevia, under the name Canalevia-CA1, is conditionally approved by the FDA as an oral prescription drug for the treatment of chemotherapy-induced diarrhea (CID) in dogs.

“In the study of 200 dogs with general diarrhea, the pre-specified primary endpoint was not met. However, an updated analysis using a simplified endpoint – defining treatment success as no further episodes of diarrhea after the first treatment – showed that dogs treated with Canalevia had significantly better outcomes than those receiving placebo, including fewer watery stools and improved fecal scores,” said Dr. Michael Guy, D.V.M., M.S., Ph.D., Jaguar’s Vice President of Preclinical and Nonclinical Studies.

“We provided the CVMP with a summary of the updated analysis of the data from our completed study, which we look forward to having the CVMP review,” Dr. Guy said. “Following the start of the procedure in mid-January, the EMA will have 60 days (extendable to 90) to indicate if they agree that this updated analysis would support approval of Canalevia for treatment of general diarrhea in dogs in the EU. If the EMA agrees that the updated analysis would support approval, the company will submit a Marketing Authorization Application to the EMA for Canalevia for general diarrhea in dogs. If the application is approved, Canalevia will be marketable for treatment of general diarrhea in dogs in all 27 EU member countries.”

Data from the European Pet Food Industry Federation indicates that there were 69,359,000 dogs in the EU in 2023. According to the American Veterinary Medical Association, there were an estimated 89.7 million dogs in the US in 2024, with nearly half (45.5%) of US households owning a dog in 2024.

“We’ve been pleased with the marketplace reception of crofelemer for treatment of CID in dogs in the US and see a meaningful opportunity in the much larger market of general diarrhea in dogs, both in the US and the EU. We estimate that US veterinarians see approximately 6 million annual cases of acute and chronic diarrhea in dogs,” said Lisa Conte, Jaguar’s Founder and CEO. “Our primary objective for Canalevia is to secure a partner to help fund and execute development and commercialization globally for treatment of general diarrhea in dogs, while we continue to support availability for CID in dogs in the US. We have made business development around general diarrhea in dogs a key focus and potential catalyst for Jaguar in 2025.”

Diarrhea is one of the most common reasons dogs are seen by general practice veterinarians and is the second most common reason for visits to veterinary emergency hospitals, yet there is currently no FDA-approved drug to treat general, non-infectious diarrhea in dogs. Devastating diarrhea-related dehydration can occur rapidly for the animal, and the lack of easy access to outdoor facilities is a significant problem for families living in urban settings with dogs.

About Canalevia^® and Canalevia^®-CA1

Canalevia contains crofelemer, Jaguar’s novel, oral plant-based drug sustainably harvested from the Croton lechleri tree, that modulates chloride channels in the gastrointestinal tract to reduce diarrhea. Importantly, Canalevia is not an antibiotic drug. The overuse and misuse of antibiotics, both in humans and animals, contribute to the development of bacteria that are resistant to antibiotics.

Canalevia-CA1 (crofelemer delayed-release tablets), available from multiple leading veterinary distributors in the US, including Chewy, is the first and only oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea (CID) in dogs. Canalevia-CA1 is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient isolated and purified from the Croton lechleri tree. Canalevia-CA1 is currently conditionally approved by the FDA under application number 141-552. Conditional approval allows for commercialization of the product while Jaguar continues to collect the substantial evidence of effectiveness required for full approval. Jaguar has also received Minor Use in a Major Species (MUMS) Designation from the FDA for Canalevia-CA1 to treat CID in dogs. FDA has established a “small number” threshold for minor use in each of the seven major species covered by the MUMS act. The small number threshold is currently 80,000 for dogs, representing the largest number of dogs that can be affected by a disease or condition over the course of a year and still have the use qualify as a minor use.

About Conditional Approval and Full Approval

Canalevia-CA1 initially received conditional approval in December 2021 from the FDA for the treatment of CID in dogs. FDA’s conditional approval allows a drug company to legally promote, advertise and sell the animal drug for the labeled uses before proving it meets the “substantial evidence” standard of effectiveness for full approval. The conditional approval is valid for one year, with up to four annual renewals, for a total of five years of conditional approval. To receive a renewal from the FDA, the company must show active progress toward proving “substantial evidence of effectiveness” for full approval. After collecting the remaining effectiveness data, the company then applies to the FDA for full approval. The FDA reviews the application and, if appropriate, fully approves the drug.

About Chemotherapy-induced Diarrhea (CID) in Dogs

According to the American Veterinary Medical Association, approximately 1 in 4 dogs will at some stage in their life develop cancer. Nearly half of dogs over 10 will develop cancer.¹ According to the National Cancer Institute at the National Institutes of Health, roughly 6 million new cancer diagnoses are made in dogs yearly in the US.

Due to the increasing number of chemotherapeutic agents, chemotherapy is fast becoming the most widely used cancer treatment in veterinary medicine. Studies have found the incidence of CID to be one of the three most prevalent side effects in dogs undergoing cancer treatment,² and managing side-effects such as diarrhea can be important to maintain successful cancer treatment. More than half of the US veterinarians who responded to a Jaguar-sponsored survey reported that CID interferes with their patients’ chemotherapy treatment plans, indicating an unmet need for an effective product for the treatment of CID.

Canalevia-CA1 is a tablet that can be given orally twice a day and can be used for home treatment of CID in dogs.

Important Safety Information About Canalevia^®-CA1

For oral use in dogs only. Not for use in humans. Keep Canalevia-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar’s Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

Canalevia-CA1, visit canalevia.com

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar’s expectation that it may identify a partner to fund and execute development and commercialization of crofelemer for the treatment of general, non-infectious diarrhea in dogs in the US and/or globally, Jaguar’s expectation that it may be possible to obtain approval of Canalevia in the EU for treatment of general diarrhea in dogs based on the results of the study Jaguar completed in 200 dogs with general diarrhea, Jaguar’s expectation that, if the submitted summary of the updated analysis of the data from the company’s completed study is acceptable to the EMA, the company will then submit a MAA for Canalevia for general diarrhea in dogs, and Jaguar’s expectation that, if the MAA is approved, Canalevia will be marketable for treatment of general diarrhea in dogs in all 27 EU member countries. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

¹ “Cancer in Pets.” American Veterinary Medical Association, 2021, https://www.avma.org/resources/pet-owners/petcare/cancer-pets

² Mason SL, Grant IA, Elliott J, Cripps P, Blackwood L. Gastrointestinal toxicity after vincristine or cyclophosphamide administered with or without maropitant in dogs: a prospective randomised controlled study. J Small Anim Pract. 2014;55:391-398

Contact:

hello@jaguar.health
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View the original press release on ACCESS Newswire

DALLAS, TX / ACCESS Newswire / December 2, 2025 / Career Management Partners (CMP), a minority- and woman-owned talent and transition firm, has been named to Hunt Scanlon Media’s 2025 Non-Profit Recruiting Top 70, which recognizes leading executive search firms serving mission-driven organizations.

Hunt Scanlon Media is a premier authority on executive search and leadership talent, known for its industry rankings and in-depth market intelligence. Inclusion in the Non-Profit Recruiting Top 70 reflects CMP’s track record of successfully delivering executive talent to organizations advancing critical causes in communities across the country.

“Nonprofit organizations need leaders who bring both operational excellence and a deep connection to mission,” said Maryanne Piña, CEO of CMP. “This recognition from Hunt Scanlon underscores our commitment to partnering with boards and executives to place leaders who elevate governance, strengthen institutions, and advance long-term organizational sustainability.”

CMP’s Executive Search practice serves organizations across industries, with a specialized pillar dedicated to nonprofits, foundations, associations, and the broader social sector-delivering a high-touch, high-tech experience. Recent nonprofit assignments include key executive roles for organizations focused on healthcare, education, housing, and family services, reflecting CMP’s breadth of sector expertise.

“Securing the right executive talent at the right moment can change the trajectory of an entire organization,” said Dr. John Carlo, CEO of Prism Health North Texas. “Our partnership with CMP ensured we had a strong, mission-aligned slate of candidates and a disciplined, highly effective search process. Their expertise removed uncertainty, strengthened our decision-making, and positioned our new leader for a successful transition.”

In addition to executive search, CMP supports clients across the full talent lifecycle, including leadership development, assessment, and outplacement solutions. CMP brings a diverse lens to every engagement, helping organizations build inclusive, future-ready leadership teams.

To learn more about CMP’s nonprofit executive search and talent solutions, visit www.careermp.com or explore CMP’s profile in Hunt Scanlon’s Select Guide to America’s Top 250 Executive Search Firms.

About CMP

CMP is a talent and transition firm in the business of developing people and organizations across the full talent lifecycle. As a minority- and woman-owned firm, we provide a diverse lens and unique results with innovative search, assessment, coaching, and outplacement solutions.

Press Contact

Name:  Cristy Reyna
Phone: 1.800.680.7768 
Email: creyna@careermp.com

Related Links

https://www.careermp.com

https://huntscanlon.com/select-guide/career-management-partners-cmp/

https://huntscanlon.com/non-profit-top-70/

SOURCE: CMP

View the original press release on ACCESS Newswire

Focused on advancing its strategy for sustainable, scalable expansion, the Company unveils its refreshed brand identity, outlines its integrated farm-to-shelf model and details its disciplined path for future growth.

VANCOUVER, BC AND BREDA, NETHERLANDS / ACCESS Newswire / December 2, 2025 / Organto Foods Inc. (“Organto” or “the Company”), (TSXV:OGO)(OTCQX:OGOFF)(FSE:OGF0), a leading provider of organic and fairtrade fruit and vegetable products, today announced key milestones underscoring its transformation into a stronger, more disciplined and growth-ready organization. Following a 21-month restructuring, the Company has streamlined operations and strengthened both its balance sheet and financial performance, positioning it for sustained, profitable expansion.

“Organto today is fundamentally sounder and better positioned for scalable growth,” said Steve Bromley, Chief Executive Officer & Co-Chair of Organto. “Over the past almost two years, we’ve repositioned and streamlined our business, strengthened our financial foundation and demonstrated our ability to grow both quickly and responsibly. With disciplined execution and a clear strategy, we’re advancing our integrated asset-efficient model, with plans to broaden our product portfolio and create long-term value for shareholders.”

Transformation Milestones and Momentum
Following a comprehensive 21-month restructuring, Organto has repositioned itself for scalable, sustainable growth:

• Strong performance: YTD Q3 2025 sales of $45.9M, up 222% year-over-year and cash operating costs as a percentage of sales reduced to 7.3% from 13.4% in the prior year, with adjusted EBITDA performance improvement year-over-year, realizing the Company’s first ever positive EBITDA quarter in Q1 2025.

• Integrated operations: Organto’s operations have been fully integrated, managing sourcing, logistics, quality control, certification and retail execution across key European markets.

• Asset-efficient model: Scalable supply chain connecting certified organic growers to leading retailers year-round, optimizing cost, speed, and sustainability across markets, and positioning for further optimization of digitally connected technologies.

• Strengthened balance sheet: Eliminated all convertible debt, improved liquidity, established new financing and foreign exchange facilities with a premier bank with deep roots in the agricultural and food sectors and established a leaner, greener and asset-efficient operating model.

• Expanded retail relationships: Serving a growing network of leading European grocers under branded, private-label, and direct-distribution programs with recurring annual commitments.

• Foundation for growth: Positioned to expand fresh product categories, evaluate market entry into North America and entry into adjacent value-added ingredient and consumer product segments.

A Refreshed Brand for a Reinvigorated Vision
To mark this new chapter the Company is today launching its modernized brand image – including an updated logo, visual system and digital presence. The move reflects the Company’s evolution into an integrated global ecosystem and aligns its visual identity with its operational structure and long-term vision, reinforcing its position as a trusted partner in transparent and responsible food systems.

The Company’s guiding principles, represented by the three symbolic leaves in its new logo, reflect the foundation of this ecosystem:

• Healthy: Providing nutritious, responsibly sourced foods that meet growing consumer demand.

• Value-Driven: Creating opportunity and shared value for growers, partners, customers, team members and shareholders.

• Sustainable: Embedding transparency, traceability, and ethical practices across every stage of its operations.

“These three principles guide what we do, from how we source and operate to how we work and grow with our partners,” added Steve Bromley. “They lead our actions with the goal of ensuring that as we scale, profitability and purpose stay aligned across our global network.”

An Integrated Global Ecosystem
At the heart of Organto’s renewed strategy is a clear purpose: to make healthy, sustainable foods reliably available through a responsible, connected global network.

Guided by this mission, Organto operates as an integrated ecosystem connecting sustainable growers, partners and retailers through an asset-efficient supply chain. By combining global sourcing, logistics and in-market retail execution, Organto transforms traditionally fragmented value chains into a coordinated farm-to-shelf system, delivering year-round availability, full traceability and scalable efficiency.

“Our integrated ecosystem connects key part of the supply chain – from grower to retailer – allowing us to minimize waste, improve efficiency and create shared value for each of our partners,” commented Steve Bromley. “Together, we are championing a smarter, more sustainable way to bring organic foods to the world.”

Built On Transparency, Trust, And Responsible Growth
Organto’s success is underpinned by a disciplined operating culture, strong governance, and a commitment to transparency at every level of its business.

• Governance and Leadership: Led by a seasoned management team with decades of experience in global food systems, finance, and organics, Organto is structured for accountability and performance. A streamlined governance model ensures clear oversight, data-driven decision-making and disciplined capital allocation.

• Product Integrity: Organto’s products meet rigorous global standards, including Organic, Fairtrade, Global G.A.P., and other certifications.

• Transparency and Traceability: Products are tracked from field to shelf through SKU-level audit trails, offering visibility into product origin, quality, and environmental impact.

• Sustainability Commitment: Organto embeds sustainability and ethical sourcing into its business model – supporting fairtrade practices and living wages across its growing regions. By minimizing waste, optimizing transport and embracing data-driven efficiencies, Organto aligns performance with environmental stewardship.

• Year-Round Supply and Scale: Through its “follow-the-sun” sourcing network and strategically located entry ports and distribution hubs, Organto targets to provide consistent year-round availability of high-demand categories.

• Established Customer Base: Organto serves a growing network of leading retail and distribution partners across Europe, including several of the continent’s largest grocery chains.

Positioned For Continued Growth
Backed by a lean, asset-efficient model and strong category expertise, Organto is well positioned to capitalize on accelerating demand for organic and fairtrade foods. The global organic food and beverage market is projected to reach around US $1 trillion by 2034¹, growing at a compound annual growth rate of 13.7% from 2025 to 2034¹, driven by increasing consumer awareness, retailer sustainability commitments and regulatory support for traceable food systems.

Even amid broader industry headwinds, including inflationary pressures, supply chain consolidation and tightening ESG standards, Organto’s integrated model delivers stability, visibility and scalability.

Organto’s refreshed brand and strengthened foundation mark a pivotal moment for the Company as it advances its strategy for sustainable, profitable growth. With a fortified balance sheet, scalable infrastructure and expanding retail relationships, Organto is advancing a disciplined strategy for sustainable growth – extending its leadership in Europe while evaluating opportunities in North America and adjacent value-added categories.

ON BEHALF OF THE BOARD
Steve Bromley
Chief Executive Officer & Co-Chair

Investor & Media Contact:
John Rathwell
SVP, Corporate Development
john.rathwell@organto.com
www.organto.com

¹ Precedence Research. Organic Food and Beverages Market Size, Growth, Trends, Report (2025-2034). Last updated Nov 6, 2025.

About Organto Foods
Organto Foods Inc. (TSXV:OGO)(OTCQX:OGOFF)(FSE:OGF0) is a Canadian-headquartered company supplying certified organic and fairtrade produce to leading international retailers. Organto manages global sourcing, logistics and distribution through an integrated, asset-efficient model that connects growers and consumers with transparency, sustainability and operational excellence.

Forward Looking Statements
This news release may include certain forward-looking information and statements, as defined by law including without limitation Canadian securities laws and the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995 (“forward-looking statements”). In particular, and without limitation, this news release contains forward-looking statements respecting Organto’s business model and markets; Organto’s belief that the Company has made solid progress in the restructuring and realignment of its business focused on a clear path to profitability, sustained growth and long-term stability; Organto’s belief that its business has been repositioned for scalable, sustained growth via its integrated operations and asset efficient business; Organto’s belief that it is well positioned to expand into new products categories, new geographies and new value-added product segments; Organto’s belief that its guiding principles will allow the profitability and purpose to remain aligned; Organto’s belief that its success is underpinned by a disciplined operating culture, strong governance and a commitment to transparency at every level of is business; Organto’s belief that it is well positioned to capitalize on accelerating demand for organic and fairtrade foods; Organto’s belief that it remains focused on building a world class company focused on growing healthy foods markets with the goal of building lasting shareholder value; management’s beliefs, assumptions and expectations; and general business and economic conditions. Forward-looking statements are based on a number of assumptions that may prove to be incorrect, including without limitation assumptions about the following: the ability and time frame within which Organto’s business model will be implemented and product supply will be increased; cost increases; dependence on suppliers, partners, and contractual counter-parties; changes in the business or prospects of Organto; unforeseen circumstances; risks associated with the organic produce business generally, including inclement weather, unfavorable growing conditions, low crop yields, variations in crop quality, spoilage, import and export laws, and similar risks; transportation costs and risks; general business and economic conditions; and ongoing relations with distributors, customers, employees, suppliers, consultants, contractors, and partners. The foregoing list is not exhaustive and Organto undertakes no obligation to update any of the foregoing except as required by law.

SOURCE: Organto Foods, Inc.

View the original press release on ACCESS Newswire

NEW YORK, NY / ACCESS Newswire / November 25, 2025 / The gold market has always relied on external verification. Inspectors examined surfaces. Traders checked paperwork. Vault operators reconciled bar lists by hand. The technology behind those steps changed only marginally over the past century. That static approach created the environment where

The industry is finally moving from external checks to internal identity. SMX (NASDAQ:SMX) is entering the 2025 DMCC Precious Metals Conference with a system designed to embed verification into the material itself. It’s a technology-first shift that alters how the market can function.

Dubai is the right stage for that transformation. The DMCC is a global center for modern commodities trade by prioritizing digital systems, traceable workflows, and higher standards for responsible conduct. Under the leadership of Ahmed Bin Sulayem, the organization has consistently adopted technologies that strengthen the integrity of the sectors it oversees. The precious metals industry within the DMCC ecosystem expects tools that keep pace with global trade.

Replacing Legacy Systems with a Technology-First Approach

That’s because legacy methods no longer keep up with the volume, speed, and regulatory expectations placed on the market. A technology capable of carrying identity through each step of movement is no longer a luxury. It’s a requirement for a system that has outgrown its traditional foundation. SMX addresses that requirement with technology that operates at the molecular level, embedding a Physical-to-Digital link that creates an identity inseparable from the metal.

It remains stable under heat, pressure, and long-term storage, providing every participant in the chain with a consistent reference point. Refiners can validate output without relying exclusively on surface markings. Vaults can confirm the authenticity of their inventory at any time. Traders can execute transactions with confidence that the asset they are handling is the same asset that entered the system.

Even established service providers in the region, including Brink’s, have shown interest in how identity systems like this can reinforce their own operational frameworks. The market is moving toward solutions that embed truth at the material level. SMX built its technology specifically for that purpose.

Identity as Infrastructure

The Physical to Digital Link operates as more than a verification tool. It becomes infrastructure the moment it enters the value chain. A bar marked at the refinery maintains its identity throughout transport, storage, and trade. That identity is not dependent on a label, a barcode, or a certificate. It is not influenced by inspection conditions or subjective interpretation. It is an internal characteristic. When the metal moves, the identity moves with it. That consistency gives the market a foundation that did not exist before, and it changes how organizations manage risk and design their workflows.

This type of identity infrastructure aligns with DMCC priorities. The center has invested heavily in raising global standards across the commodities it oversees. It attracts institutions that want confidence in the assets they handle and transparency in their operational environment. A technology that gives each bar a permanent identity supports every part of that strategy. It reduces friction between market participants. It minimizes disputes during settlement. It increases audit trail accuracy without requiring additional administrative layers. It is a bottom-up improvement that strengthens every top-down control.

This is also where SMX stands apart. Many companies in the metals ecosystem have attempted to solve visibility issues by adding additional documentation or digital recordkeeping. SMX approaches the challenge from within the material rather than around it. By starting at the molecular level, SMX technology bypasses the limitations that have historically led to inconsistent identity. It creates a system that the market can build on regardless of location, handler, or trading platform. As the global gold sector seeks to modernize without sacrificing efficiency, technologies that operate with this degree of permanence become indispensable. At the right time.

A New Standard for Precision in Precious Metals

Technological advancement in the gold market has always been incremental. Scales became more accurate. Testing methods improved. Reporting systems digitized. None of those developments changed the fundamental structure behind how identity was established. SMX’s technology does. It replaces a chain of subjective assessment with a chain of measurable facts. That redefines how institutions can evaluate risk, price assets, and manage operational exposure. It also serves the growing expectation that responsible sourcing and a clear chain of custody must be verifiable rather than assumed.

Dubai’s prominence amplifies this shift. The DMCC Precious Metals Conference draws institutions that recognize the market is entering a transition period. They understand that the next decade will be shaped by the technologies that provide certainty at scale. SMX is entering that environment with a system already demonstrated in major gold hubs, including Dubai, where even long-standing logistics partners have seen its value. The market does not need promises. It needs tools that function under the pressures of real trade flows. SMX’s identity technology delivers that reliability.

As the conference unfolds, one reality is becoming crystal clear. The gold market is no longer defined by how the metal looks on the surface. It’s defined by what the material carries within it. SMX built a system that gives the world’s most trusted asset a way to prove itself at every stage of its journey. It’s a technology-first approach that brings precision, accountability, and modern infrastructure to a sector ready for change. The next chapter of the gold market will be written by the companies that make verification part of the asset. SMX is arriving at DMCC prepared to lead that shift.

About SMX

As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

Forward-Looking Statements

The information in this press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “will,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements in this press release may include, for example: matters relating to the Company’s fight against abusive and possibly illegal trading tactics against the Company’s stock; successful launch and implementation of SMX’s joint projects with manufacturers and other supply chain participants of steel, rubber and other materials; changes in SMX’s strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects and plans; SMX’s ability to develop and launch new products and services, including its planned Plastic Cycle Token; SMX’s ability to successfully and efficiently integrate future expansion plans and opportunities; SMX’s ability to grow its business in a cost-effective manner; SMX’s product development timeline and estimated research and development costs; the implementation, market acceptance and success of SMX’s business model; developments and projections relating to SMX’s competitors and industry; and SMX’s approach and goals with respect to technology. These forward-looking statements are based on information available as of the date of this press release, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Accordingly, forward-looking statements should not be relied upon as representing views as of any subsequent date, and no obligation is undertaken to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. As a result of a number of known and unknown risks and uncertainties, actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include: the ability to maintain the listing of the Company’s shares on Nasdaq; changes in applicable laws or regulations; any lingering effects of the COVID-19 pandemic on SMX’s business; the ability to implement business plans, forecasts, and other expectations, and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which SMX operates; the risk that SMX and its current and future collaborators are unable to successfully develop and commercialize SMX’s products or services, or experience significant delays in doing so; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that SMX is unable to secure or protect its intellectual property; the possibility that SMX may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described in SMX’s filings from time to time with the Securities and Exchange Commission.

Contact: info@securitymattersltd.com

SOURCE: SMX (Security Matters) Public Limited

View the original press release on ACCESS Newswire